Alnylam Pharmaceuticals, Inc.
ALNY
$473.29
$8.361.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 113.11% | -337.46% | 18.78% | 36.82% | 34.83% |
| Total Depreciation and Amortization | -8.05% | -34.08% | -44.94% | -59.38% | -76.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 54.74% | 0.37% | 10.25% | -1.20% | -1.37% |
| Change in Net Operating Assets | -749.30% | -194.40% | -925.96% | -414.35% | -440.74% |
| Cash from Operations | 370.10% | -104.17% | -123.85% | -107.98% | 2,766.45% |
| Capital Expenditure | -9.90% | 31.55% | 50.61% | 44.90% | 40.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 276.11% | 67.97% | 135.59% | 69.88% | -58.08% |
| Cash from Investing | 238.08% | 61.15% | 119.69% | 65.26% | -29.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -17.80% | 28.26% | 149.30% | 105.44% | 71.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,553.51% | -334.90% | -172.20% | -135.64% | -79.76% |
| Cash from Financing | -205.66% | -0.51% | 99.99% | 70.89% | 54.01% |
| Foreign Exchange rate Adjustments | 80.73% | 551.88% | 252.99% | -338.44% | 547.84% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 480.05% | -53.52% | 3,174.45% | 386.50% | 267.47% |